

SEP 24 2008



**HAMRE, SCHUMANN,
MUELLER & LARSON, P.C.**
AN INTERNATIONAL INTELLECTUAL PROPERTY LAW FIRM

FAX TRANSMISSION September 24, 2008

TO: Mail Stop: OIPE Filing Receipt Correction
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FROM: Douglas P. Mueller

OUR REF: 20039.0006USWO

TELEPHONE: (612) 455.3800

Total pages, including cover letter: 5


PTO FAX NUMBER: 571.273.8300

If all pages are NOT received, please call us at 612.455.3800 or fax us at 612.455.3801.

Title of Document: **Request for Corrected Filing Receipt (1 page),
Copy of Filing Receipt showing correction (3 pages)**


Applicant: FUKUMOTO, et al.
Serial No.: 10/589,443
App. Filed: May 7, 2007
Group Art No.: 1625
Confirmation No.: 7172

Please charge any additional fees or credit overpayment to Deposit Account No. 50-3478. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: 
Name: Douglas P. Mueller
Reg. No.: 30,300

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Mary Ann Studanski


Signature

September 24, 2008
Date

225 SOUTH SIXTH STREET · SUITE 2650 · MINNEAPOLIS · MN 55402
TEL. 612.455.3800 · FAX 612.455.3801
WWW.HSML.COM · MAIL@HSML.COM

RECEIVED
CENTRAL FAX CENTER

SEP 24 2008

S/N 10/589,443

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	FUKUMOTO, et al.	Examiner:	Unknown
Serial No.:	10/589,443	Group Art Unit:	1625
Filed:	May 7, 2007	Docket No.:	20039.0006USWO
Title:	PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF		

CERTIFICATE UNDER 37 CFR 1.6(d):

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on September 24, 2008.

By: 

Name: Mary Ann Studanski

REQUEST FOR CORRECTED FILING RECEIPT

Office of Initial Patent Examination's Customer Service Center
Assistant Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is a photocopy of the Corrected Filing Receipt from the United States Patent and Trademark Office in the above-identified application showing an additional requested correction.

The Assignee's full corporate name is incorrect.

Please replace [[Takeda Pharmaceutical Company]] with Takeda Pharmaceutical Company Limited.

Correction of the records of the United States Patent and Trademark Office and issuance of a corrected filing receipt are respectfully solicited.

52835

PATENT TRADEMARK OFFICE

Dated: September 24, 2008

DPM/mas

Respectfully submitted,

HAMRE, SCHUMANN, MUELLER &
LARSON, P.C.
P.O. Box 2902-0902
Minneapolis, MN 55402-0902
(612) 455-3800

By: 

Douglas A. Mueller
Reg. No. 30,300

SEP 24 2008



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1418
Alexandria, Virginia 22313-1418
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLAIMS	IND CLAIMS
10/589,443	05/07/2007	1625	2680	20039.0006USWO	28	1

CONFIRMATION NO. 7172

CORRECTED FILING RECEIPT

52835
HAMRE, SCHUMANN, MUELLER & LARSON, P.C.
P.O. BOX 2902
MINNEAPOLIS, MN 55402-0902

Date Mailed: 07/28/2008

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Shoji Fukumoto, Osaka-shi, JAPAN;
Takeshi Yamamoto, Osaka-shi, JAPAN;
Masanori Okaniwa, Osaka-shi, JAPAN;
Toshimasa Tanaka, Osaka-shi, JAPAN;Assignment For Published Patent Application Limited
Takeda Pharmaceutical Company, Osaka, JAPANPower of Attorney: The patent practitioners associated with Customer Number 52835

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP05/03086 02/18/2005

Foreign Applications

JAPAN 2004-042491 02/19/2004

If Required, Foreign Filing License Granted: 08/27/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 10/589,443**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

SCANNED

10

RECEIVED
CENTRAL FAX CENTER

SEP 24 2008

Title

Pyrazoloquinolone Derivative And Use Thereof

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER**Title 35, United States Code, Section 184****Title 37, Code of Federal Regulations, 5.11 & 5.15****GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

page 2 of 3

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).